How do I hire a fractional head of revenue for a life sciences company in 2027?

The job this role is actually hired to do

A fractional head of revenue is not a part-time employee. The distinction matters because it changes what you should ask for and what you should be willing to pay. An employee is hired for capacity — a body in a seat, forty-plus hours, indefinite duration. A fractional revenue leader is hired for a *decision surface*: which segments to chase, which deals to walk away from, what the pipeline actually contains versus what the CRM claims it contains, and what a credible forecast looks like when a single order can move the quarter by twenty percent.

In life sciences specifically, that decision surface is unusually expensive to get wrong. Consider the shape of the sale. A research-tools company selling instruments into academic core facilities is selling against a grant cycle it does not control. A diagnostics company is selling into a hospital lab where the economic buyer, the technical evaluator, the compliance reviewer, and the person who actually signs are four different people with four different definitions of "value." A CRO or CDMO selling services into biotech is selling against a program milestone that can be cancelled by a data readout nobody in the room can predict. None of these look like a mid-market SaaS sale where a director signs a $40K annual contract after a two-week trial.

So the job description, written honestly, is usually one of five things:

Building a first commercial motion. The founders — often scientists — have closed the first handful of customers through their own network and reputation. Revenue exists but is not repeatable. The fractional leader's job is to reverse-engineer why those deals closed, write it down as a qualification standard, and prove it works on a cohort of deals the founders did not personally source. This is the most common seed-to-Series-A engagement and it is mostly a documentation and instrumentation job disguised as a sales job.

Unsticking a stalled pipeline. There is pipeline, sometimes a lot of it, and it is not converting. The usual root causes in this vertical: deals qualified on scientific enthusiasm rather than budget authority, no identified funding source, evaluation protocols that were never scoped with an end date, and a champion who is a bench scientist with no procurement leverage. The fix is unglamorous — a qualification framework, a mutual action plan template, and the discipline to close-lose things that have not moved in two quarters.

Preparing for a raise or a diligence process. Investors will pressure-test cohort retention, sales-cycle length, win rate by segment, and forecast accuracy against prior guidance. A fractional leader who has been through this before knows what the data room needs to contain and, more usefully, knows which numbers not to present. This engagement is often only three to five months and is priced accordingly.

Bridging a departure. The VP of Sales left, the replacement search will take five to seven months, and someone needs to run the weekly forecast call and keep the team from freelancing. This is the closest thing to an interim executive role and usually demands more days per month — fifteen to twenty — than a purely strategic engagement.

Coaching a founder who is and will remain the closer. Common in high-ACV therapeutics tooling and in service businesses where the scientific founder's credibility *is* the differentiator. Here the fractional leader builds the infrastructure around the founder rather than replacing them: pre-call research, follow-up discipline, a real handoff to implementation, and a pipeline review the founder cannot talk their way around.

Naming which of these five you are buying, in writing, before you interview anyone, eliminates most of the failure modes. The engagements that go badly are almost always ones where the company thought it was buying strategy and the operator thought they were being hired to close deals, or vice versa.

A short note on titles, because the market uses them loosely. A fractional CRO implies ownership of the full revenue function — sales, marketing, customer success, partnerships, and the RevOps layer underneath. A fractional VP of Sales owns the selling motion only. A fractional CCO in life sciences sometimes also owns market access and reimbursement strategy, which is a genuinely different skill set. If your marketing function is one contractor and a website, hiring a "CRO" who only knows how to run a sales team leaves the demand problem untouched. Match the title to the scope of the gap, not to the seniority you wish you could afford.

How the role fits the RevOps stack around it

A fractional revenue leader arriving into an instrumented company can be useful in week two. Arriving into an uninstrumented one, they will spend their first month doing archaeology, and you will have paid senior rates for data cleanup. Understanding where the role sits in the operating stack is what lets you decide whether to hire the leader first or the operations underneath them first.

The dependency is real. Forecast accuracy is a function of stage definitions plus data hygiene plus rep honesty. A fractional leader can fix stage definitions in a week and rep honesty in a quarter, but they cannot fix data hygiene without either an admin or a lot of their own retainer days spent in the CRM — which is the most expensive possible use of that retainer.

Read that diagram as a build order, not just a map. The leader defines the top row. The RevOps layer implements it. If the RevOps layer does not exist, one of three things happens: the leader does it themselves at $600–$1,200 an effective hour, you hire a part-time admin or a small RevOps agency alongside them at a fraction of that rate, or nothing gets implemented and you re-litigate the same pipeline questions every month.

The economically sensible answer, for most companies under roughly $10M in revenue, is the middle one. Pair the fractional leader with ten to twenty hours a month of operations support. Many fractional practitioners have a preferred operator they bring with them; ask about this in the first conversation, because it tells you whether they think in systems or only in deals.

The regulatory branch on the right side of that flow is the piece generalists miss. In a medical device or diagnostics company, sales collateral, comparative claims, and even a demo script can fall under quality-system controls and promotional-review requirements. A revenue leader who ships a new one-pager without routing it through regulatory review is creating an audit finding, not a growth lever. When you interview, ask directly: *who reviewed your sales collateral at your last life sciences company, and how long did that review take?* Someone with real experience will answer in days-of-turnaround and will have opinions about how to keep it from becoming a bottleneck. Someone without it will look confused by the question.

There is a downstream effect worth planning for as well. Whatever qualification standard the fractional leader installs becomes the thing your future full-time VP inherits — or rips out. Ripping it out is a two-quarter setback. Building the standard in documented, portable form (written definitions, CRM-enforced required fields, a recorded training session) is the difference between an engagement that compounds and one that evaporates on the last invoice. Make documentation an explicit deliverable, not an assumed courtesy.

Pricing, engagement models, and what actually drives the number

Fractional pricing is not standardized, and anyone quoting a single market rate is selling something. What *is* consistent is the set of variables that move the number. Understanding them lets you negotiate on structure rather than haggling on a monthly figure.

Days per month is the primary driver. The market convention is a retainer covering a defined number of days — commonly eight to twenty. Below roughly eight days, an operator can review pipeline and advise, but cannot own an outcome; expect to get a coach, not a leader, and price accordingly. Ten to twelve days supports a real strategic engagement with weekly forecast ownership. Fifteen to twenty days is effectively an interim executive and prices close to a fractional equivalent of a full-time base salary, which is often still cheaper once you account for benefits, employer taxes, equity, and the severance risk on a bad full-time hire.

Scope of ownership. Advisory-only — reviewing pipeline, coaching the founder, sitting in on the board call — sits at the bottom of the range. Carrying a number, owning the team, and being on customer calls sits at the top. The delta between these is frequently two to three times, for the same nominal day count, because the second one carries reputational risk for the operator.

Domain scarcity. This is where life sciences diverges sharply from generalist markets. The population of revenue leaders who have carried a number selling capital equipment into core labs, or diagnostics into IDNs, or CDMO services into clinical-stage biotech, is small. Scarcity pricing is real and you should expect a premium over a generalist B2B fractional CRO. Whether that premium is worth paying depends on how much of your sales difficulty is domain-specific: if your buyer is a lab director with a grant-funded budget, it is worth a great deal; if you sell software to commercial ops teams at pharma and the motion resembles enterprise SaaS, a strong generalist with pharma-adjacent experience may be entirely sufficient at a lower rate.

Cash versus equity. Pre-revenue and seed-stage companies frequently offer equity to reduce the cash burden. Advisor-grade equity grants are common, typically vesting monthly over one to two years with a cliff of three to six months, and often carry a double-trigger acceleration clause. Treat this as a genuine negotiation, not a discount lever — an operator who takes meaningful equity is buying into the outcome, and the reverse is also true: an operator who *refuses* any equity may be telling you something about their read on your prospects. Get equity documented in a separate advisor agreement, not buried in the services contract, and have counsel confirm the tax treatment of the grant type before either party signs.

Travel and conference load. Life sciences is still a conference-driven market. Society meetings, trade shows, and customer site visits matter here in a way they no longer do in pure software. Decide up front whether travel days count against the retainer day count or are billed separately, and who covers expenses. This single clause causes more mid-engagement friction than pricing does.

Three engagement structures cover almost every real case:

Flat monthly retainer, fixed days. Simplest and most common. Predictable for both sides. Weakness: it rewards presence, not outcomes, so pair it with milestones.

Retainer plus outcome bonus. A lower base with a bonus tied to something measurable — qualified pipeline created, deals closed, forecast accuracy within a band, a completed CRM migration. Life sciences cycles are long enough that closed-won bonuses inside a 90-day window are often unachievable, so pipeline-quality and process milestones are usually the honest choice. If you do use closed-won, define it against contracts signed rather than revenue recognized, since recognition can trail signature by quarters in this vertical.

Project fee for a defined deliverable. A pricing study, a segmentation analysis, a diligence-readiness package, a territory plan. Clean scope, clean exit, no ambiguity. Good for a first engagement with someone you have not worked with — a paid audition that costs less than a bad quarter.

Whatever the structure, three contract terms are non-negotiable from the buyer's side: a 30-day notice clause on both sides, explicit IP assignment covering playbooks and documentation created during the engagement, and a confidentiality clause that accounts for the fact that this person will see your clinical roadmap and your customer list. Add a conflicts clause naming specific competitors they may not simultaneously serve — most fractional operators carry two to four clients at once, and you are entitled to know that the adjacent client is not the company beating you in bake-offs.

One more caution on the low end of the market. If a quoted rate seems dramatically below what the scope implies, the usual explanation is that the person is between full-time roles and treating your company as a bridge. That is not automatically disqualifying — some of the best interim leaders arrive this way — but you should ask directly about their intent and expected duration. Discovering in month four that your revenue leader has accepted a full-time role elsewhere is a recoverable problem only if you saw it coming.

How to evaluate, shortlist, and reference-check

The hiring failure mode in this market is charisma. Fractional revenue leaders are, by selection, people who are good at selling — and the thing they are best at selling is themselves. A structured process is not bureaucracy here; it is the only defense against a very well-run pitch.

Sourcing. Start with the narrowest channels and widen. Your own investors and board members have seen operators work; ask for names of people they have watched deliver, not people they merely know. Portfolio-company CEOs in adjacent verticals are the second-best source, because they will tell you the truth about someone in a way a reference call never will. Professional communities for revenue leaders and RevOps practitioners are a reasonable third channel, and LinkedIn search works if you search for *employers* rather than titles — filter for people who have spent years at recognizable tools, diagnostics, device, or services companies, then check whether they carried a number or sat in a staff role. Someone who was a product marketer at a sequencing company is not the same as someone who ran the commercial team there, and the profile language will not always make that obvious.

Expect referral fees to come up if you source through a recruiter or a matching platform. Clarify who pays and on what basis before you take an introduction.

The screen. Thirty minutes, and you are testing for one thing: can this person describe your buyer better than you can? Ask them to walk you through the last deal they closed in a regulated market, end to end. Listen for whether they name roles and mechanics unprompted — the lab director versus the procurement lead versus the quality reviewer, capital budget cycles versus operating budget, sole-source justifications, GPO or IDN contracting, evaluation protocols, reagent rental or placement structures, grant timing. Someone with real reps will produce this detail without being asked. Someone without it will keep returning to generic frameworks and stakeholder-mapping language.

The working session. For finalists, pay for two to four hours of real work and watch them do it. Give them read access to a slice of your pipeline and ask for a written assessment: which deals are real, which are not, what is missing from your qualification, and what they would change in the first thirty days. This is the single highest-signal step in the entire process and almost nobody does it. You learn how they think, how they write, and whether they can be direct with you about bad news — which is the whole job. Pay their standard rate for the time; it is worth it, and refusing to pay filters out the people you most want.

Structured interview questions that actually discriminate:

• *Walk me through how you built a forecast for a pipeline with twelve-to-eighteen-month cycles. What did you review weekly, and what did you deliberately ignore?*
• *Tell me about a deal you lost late in the cycle. What was the actual cause, and what did you change afterward?*
• *You have a founder-CEO who is the best closer in the company and has strong opinions. How do you divide labor, and what happens when you disagree in front of a customer?*
• *Describe a time you told a board something they did not want to hear about the number.*
• *What did you hand over at the end of your last engagement, and can you describe its contents?*
• *Which parts of a life sciences sale do you find genuinely hard, and where do you rely on others?*

The last two are the most revealing. An operator who cannot describe their handoff artifact has never built one. An operator who claims nothing is hard is either inexperienced or not being straight with you.

References, done properly. Two former clients minimum, and insist on at least one where the engagement ended rather than one currently in flight. Ask closed questions that are hard to deflect: Did forecast accuracy improve, and by roughly how much? Did the sales cycle shorten? What did they leave behind that you still use today? What did you have to do yourself that you expected them to do? Would you hire them again for the *same* problem, or a different one? That last phrasing surfaces mismatches that a general "would you rehire" question papers over.

The pilot. Ninety days, three milestones, 30-day notice both directions. Reasonable milestones for a life sciences engagement: a completed pipeline audit with a written disposition for every open opportunity by day thirty; an installed qualification standard and a functioning weekly forecast call by day sixty; and by day ninety, either a defined quantum of newly qualified pipeline or a documented, trained-in process — not necessarily closed revenue, because a twelve-month cycle makes closed-won in ninety days a matter of luck rather than skill. Judging a fractional leader on closed-won inside one quarter in this vertical is judging them on deals that were already in flight before they arrived.

Common mistakes, stated plainly. Hiring a generalist and expecting them to absorb the domain on your time. Under-scoping days and then being disappointed by shallow work. Withholding CRM and call-recording access for the first month. Expecting a fractional leader to build culture or run a hiring loop — that is full-time work. Skipping the pilot because the person is impressive. And the quiet one: hiring a fractional head of revenue when the actual problem is product-market fit, which no revenue leader can fix and which they will spend six months politely failing to fix.

A decision framework for fractional versus the alternatives

Before you run any search at all, it is worth confirming that a fractional revenue leader is the right instrument. Three other options compete for the same budget: a full-time VP, a RevOps hire underneath the founder, or a specialist consultant on a defined project. Each wins in different conditions.

Working through the branches:

Fractional wins when the sales cycle is long and complex enough that judgment matters more than daily rep management; when you are under roughly $5M in revenue and a full-time senior hire would consume an irresponsible share of runway; when a scientific founder is the primary closer and needs a strategist rather than a replacement; and when your funding position makes a twelve-month full-time commitment genuinely risky. It also wins as a *bridge* — running the function competently while you search for the permanent leader, which typically takes five to seven months for a senior commercial role in this vertical.

Full-time wins when the motion is proven and the constraint is scale — hiring, onboarding, territory design, quota setting, day-to-day management of a growing team. It wins when culture-building matters, because you cannot outsource that ten days a month. And it wins when your cycle is short enough that deals need daily attention rather than weekly review.

RevOps-first wins more often than most founders expect. If your CRM is unreliable, no revenue leader — fractional or full-time — can produce a trustworthy forecast, and you will pay executive rates for data janitorial work. Spending three months and a much smaller budget on an operations contractor to establish a clean object model, enforced stage definitions, and basic reporting makes the subsequent leadership hire dramatically more productive. This sequencing decision is the highest-leverage one on the whole diagram.

Specialist project wins when the gap is narrow and knowable: a pricing and packaging study, a market-access strategy, a channel and distributor assessment for an international launch, a partner-program design. These are bounded problems with bounded costs, and hiring a general revenue leader to solve one of them is overpaying for scope you will not use.

A note on adjacent verticals, because the pattern generalizes. The same decision tree applies almost unchanged in medical devices, in clinical-stage services, in laboratory informatics, and — outside of health entirely — in industrial equipment and defense-adjacent hardware. The common thread is long cycles, multi-stakeholder committees, procurement gatekeeping, and a technical founder whose credibility carries the early deals. If you are drawing on a candidate pool beyond life sciences proper, these adjacent markets are where the transferable operators live. A fractional leader who ran commercial for a capital-equipment manufacturer selling into industrial QC labs will adapt to a research-tools company far faster than a SaaS leader with a nominally healthcare-flavored resume.

Finally, plan the exit at the start. Every good fractional engagement ends — by conversion, by handoff, or by completion. The best ones leave behind a documented qualification standard, a working forecast cadence, a clean CRM, recorded training, and a shortlist of candidates for the eventual full-time role. Write those artifacts into the contract as deliverables. The company that does this gets compounding value from a temporary hire; the company that does not gets a good quarter and starts over.

Related questions

What is the difference between a fractional CRO and a sales consultant?

A fractional CRO holds operational ownership — they run the forecast call, make deal decisions, and are accountable for a number. A consultant advises and produces recommendations without holding the outcome. Ownership is the dividing line, and it should be explicit in the contract.

Should a pre-revenue biotech hire a fractional revenue leader at all?

Usually not. Before first commercial traction, the binding constraint is product-market fit and scientific validation, which no revenue leader resolves. Wait until founder-led selling has produced several closed deals, then hire someone to make that motion repeatable.

How many clients does a typical fractional executive serve simultaneously?

Most carry two to four concurrent engagements. Ask directly, ask about the mix, and get a conflicts clause naming competitors they may not serve. Someone at five or more clients is unlikely to have the bandwidth for an interim-level scope.

Can the same person cover both revenue leadership and RevOps?

Occasionally, at very small scale, but it is expensive. Executive-rate hours spent on CRM administration are poor value. Pair the leader with cheaper operations support and keep the senior time on segmentation, pricing, forecast, and deals.

What should be in the handoff when the engagement ends?

A written qualification standard, documented stage definitions, the forecast model and its cadence, pipeline dispositions, recorded training sessions, pricing and discount rules, and a candidate shortlist for the permanent role. Contract these as deliverables rather than assuming goodwill.

FAQ

How is a fractional head of revenue priced?

Almost always as a monthly retainer against a defined number of days, commonly eight to twenty. The number moves with day count, whether they carry a quota or only advise, and how scarce their domain experience is. Equity frequently supplements cash at seed stage. Ask what a day means to them — some count only client-facing hours, others count everything including prep and internal work — because that definition changes the effective rate more than the headline figure does.

How long before results are visible?

Sixty to ninety days for process and forecast improvements; substantially longer for closed revenue, because a twelve-to-eighteen-month cycle means most deals closing in your first two quarters were already in motion. Judge the early period on pipeline quality, qualification discipline, and forecast accuracy against stated guidance. Anyone promising a revenue transformation in thirty days either does not understand this market or is telling you what you want to hear.

Can the engagement be fully remote?

Partially. Weekly operating rhythm, forecast calls, and coaching work fine remotely. Society meetings, trade shows, key customer site visits, and lab walkthroughs generally do not. Settle travel expectations before signing — how many trips per quarter, whether travel days consume retainer days, and who pays expenses. Unresolved travel terms are the most common source of mid-engagement friction in this vertical.

What happens if it is not working?

The 90-day pilot with 30-day mutual notice exists precisely for this. End it cleanly, collect the documentation you contracted for, and treat the diagnosis as useful information. Experienced fractional operators expect this structure and rarely take it personally. The genuine risk is not a failed pilot — it is drifting into month seven of an engagement nobody has honestly evaluated.

Do I need a fractional CRO or a fractional VP of Sales?

Match the title to the gap. A CRO owns sales, marketing, customer success, and the RevOps layer; a VP of Sales owns the selling motion only. If demand generation is your bottleneck and you hire a pure sales leader, the bottleneck survives the hire. If your marketing is strong and deals stall in the funnel, the narrower and cheaper VP scope is the better buy.

How do I verify someone truly knows life sciences selling?

Make them describe a specific deal in mechanical detail — named buyer roles, budget source, procurement path, evaluation protocol, contracting vehicle, and what nearly killed it. Real experience produces this unprompted and with texture. Absent that, you will hear frameworks and stakeholder-mapping vocabulary with no specifics attached, which is the reliable tell.

Sources

• U.S. Food and Drug Administration
• European Medicines Agency
• U.S. Bureau of Labor Statistics — Occupational Outlook Handbook: Sales Managers
• Harvard Business Review
• MIT Sloan Management Review
• First Round Review
• Y Combinator Library
• SEC EDGAR — company filings and disclosures
• National Institutes of Health — Grants & Funding

Related on PULSE

• How to structure a 90-day pilot for any fractional executive hire
• When to hire RevOps before you hire a revenue leader
• Forecasting pipeline with 12-to-18-month sales cycles
• Fractional CRO vs full-time VP of Sales: the cost and risk comparison
• Building a qualification standard your founders will actually use
• What to document before a fractional engagement ends